Zealand and Xeris both released their respective Q4 ’18 earnings. Of note, Xeris did not have an associated call for investors. Recall, Xeris’s Gvoke glucagon rescue product PDUFA date is on June 10, 2019, and Zealand remains on track to file an NDA for its dasiglucagon HypoPal by YE ’19. Below, FENIX provides highlights and insights from the respective earnings releases.